Psyence BioMed execs to meet US stakeholders on ibogaine research
Psyence BioMed's executive team will visit the U.S. to engage with researchers, institutions, industry leaders, and government stakeholders on advancing psychedelic medicine research and policy, particularly concerning ibogaine. This initiative follows recent U.S. policy developments supporting increased research collaboration. The company aims to educate stakeholders on the complexities of manufacturing pharmaceutical-grade ibogaine under GMP standards, leveraging its vertically integrated operations in Africa through PsyLabs. CEO Jody Aufrichtig also sent a formal letter to President Trump and U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., commending the Administration's leadership.
Key Highlights
- Psyence BioMed executive team to visit the U.S. for stakeholder engagement on psychedelic medicine.
- Meetings will focus on advancing ibogaine research and policy following recent U.S. policy developments.
- Company aims to educate stakeholders on GMP-compliant pharmaceutical-grade ibogaine manufacturing.
- CEO Jody Aufrichtig sent a letter to President Trump and Secretary Kennedy Jr. applauding research initiatives.
- Psyence BioMed operates GMP-compliant ibogaine manufacturing in Africa through its investment in PsyLabs.
- Company notes increased engagement from U.S. researchers seeking ibogaine supply information.
- Believes it is among a limited number of organizations globally producing natural, pharmaceutical-grade ibogaine at scale.
Price Impact
More from PBM